Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 3/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416474 | 0.88 | LMNA (0.44) | LMNANPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL6419920 | 0.87 | NPC1 (0.43) | LMNANPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL6416080 | 0.83 | MAPT (0.47) | LMNANPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL6422181 | 0.82 | NPC1 (0.40) | LMNANPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL6417991 | 0.82 | NPC1 (0.45) | LMNANPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL6418182 | 0.80 | NPC1 (0.43) | LMNANPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL6415466 | 0.80 | LMNA (0.38) | LMNANPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL6416980 | 0.76 | MAPT (0.39) | MAPTPOLBGAATP53 | |
| SCHEMBL6436435 | 0.75 | POLB (0.37) | LMNANPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL6415943 | 0.74 | MAPT (0.44) | LMNANPC1RAB9ASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119489-A1 | 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor | BAYER HEALTHCARE AG (DE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119489-A1 | 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor | HTR2C, HTR2A, HTR2B | LMNA 4582/4885NPC1 3266/4885RAB9A 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.